echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Chemicals Industry > International Chemical > Clariant and IGL of India create a renewable ethylene oxide derivative joint venture

    Clariant and IGL of India create a renewable ethylene oxide derivative joint venture

    • Last Update: 2021-08-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Sinochem News Online on July 1, Swiss specialty chemicals company Clariant announced the creation of a renewable ethylene oxide (EO) derivative joint venture with India Glycol Co.
    , Ltd.
    (IGL)
    .


    The joint venture will operate under the name IGL Clariant Specialty Chemicals Sdn Bhd


    The joint venture was originally announced in March 2021 and is now effective.


    Clariant will fully integrate the joint venture on July 1, 2021, and expects that by fiscal year 2021, revenue from the care chemicals business area will increase by approximately 50 million Swiss francs




    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.